• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

Options-360x240.png
August 1, 2022
James Miessler

There’s been considerable skepticism about using decentralized trial (DCT) approaches in cancer trials, with procedural complexity, nature of disease and other considerations lending themselves more to in-person visits. But a new survey shows cancer patients have greater interest in trials when remote technology cuts down on travel and other participation burdens.

The survey conducted by researchers at the American Cancer Society Cancer Action Network and published in JAMA Network Open found that 85 percent of respondents said they’d be more open to joining a trial with activities carried out at a local facility, and 82 percent said they would participate in a trial that uses wearable technology to capture trial data.

The 1,183 cancer patients/survivors responding to the survey were asked about nine specific remote modifications that decreased the need to travel to a site. All nine received positive responses from the majority, including:

  • Health apps to track trial data (81 percent);
  • Oral trial medications delivered to and taken at home (81 percent);
  • Trial check-ins by video from home (77 percent);
  • Virtual informed consent (77 percent);
  • Trial activities by video from home (73 percent);
  • Injectable trial medications given at home by trial staff (67 percent); and
  • IV trial medications given at home by trial staff (60 percent).

Even patients who initially said they would not join a trial for any reason reported an increase in willingness when presented with remote choices, the researchers noted.

But a minority of respondents said these options would actually decrease their willingness to join a trial. For instance, 20 percent of respondents said that IV medications delivered to and infused in the home by trial staff would deter them from joining a trial.

Nancy Sacco, head of clinical/site development operations for SiteBridge Research, an integrated research organization in Chapel Hill, N.C., says that traveling can be especially burdensome for cancer patients, who may worry about being exposed to other infections and diseases, for example, or find leaving home difficult if surgery has been part of their treatment regimen.

While cancer patients have been open to participating remotely to some degree in her experience, a hybrid trial may be the ideal way to go for piquing interest, both for patients open to remote approaches and patients against them.

Thinking carefully about what can and should be carried out remotely in a trial should be done from the very start, not implemented through an amended protocol or as a “rescue” measure for trials struggling to retain and recruit, she cautioned.

“[Patients] do not necessarily prefer completely remote clinical trials. Being seen periodically by the principal investigator is important to patients,” she told CenterWatch Weekly. “It does provide a sense of comfort and a sense of medical care that telemedicine visits and at-home care by a nurse or technologist do not necessarily fulfill.”

The survey findings back up this point: 86 percent of respondents noted that the option to do in-person visits was still an important consideration, even when enrolling in a trial in which all activities could be done at home.

Respondents’ average age was 58 and the race/ethnicity breakdown was 70 percent White patients and survivors; 20 percent Black; 3 percent Native American; and 2 percent Asian and Pacific Islander. Only 10 percent of respondents named Hispanic, Latinx or Spanish as their ethnicity.

From Sacco’s perspective, there’s room to make cancer trials more of a hybrid activity, though this will of course depend on the type/stage of cancer, the procedures involved and the dosing regimen, and may not be as easily done in oncology compared to other disease areas, such as diabetes and arthritis.

For example, many cancer treatments are drug infusions that involve special setups, administration by infusion nurses, preparation by a pharmacist prior to dosing and more complex storage requirements. In addition, cancer often involves more imaging than other diseases, which can’t be done at home when PET or CAT scans, for example, are required. For these reasons, cancer trials have been slower to move in a more DCT direction than other areas — but it’s not a space that can’t be decentralized, Sacco said.

“The changes are slower for oncology than other therapeutic indications,” she said. “There’s still a way to go, likely because oncologists need to shift some of their thinking on how these patients can be treated remotely and influence a bit more the sponsor study designs and the patients, who may have felt the negative impact of lockdown and now want to get back to the physician offices, infusion clinics, etc.”

“I do think it’s possible to redesign the clinical study approach for DCT if and as the protocol allows,” she said.

Read the full study findings here: https://bit.ly/3vh6qQF.

 

To view more CenterWatch Weekly stories, click here.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing